| Literature DB >> 34941046 |
Pengsen Guo1, Huawu Yang2, Jinhua Zhou1, Rui Mao1, Dafang Zhan2, Tongtong Zhang3, Jiang Yuan4, Yanxi Ou5, Yanjun Liu1,2.
Abstract
ABSTRACT: Few studies have reported an increase in vitamin B12 (VitB12) levels after bariatric surgery. This study reports the phenomenon and adverse reactions of serum VitB12 elevation 1 month after surgery and explores the possible etiologies.Retrospective analysis was performed on VitB12 data for 112 patients from January 2018 to October 2019. Then, 87 patients were included between November 2019 and August 2020. They were divided into 2 groups according to the level of VitB12 after surgery, and the demographic and clinical data were analyzed. Then, LASSO regression model analysis and multiple logistic regression analysis were performed to explore the risk factors for VitB12 elevation after surgery.Retrospective data showed that the VitB12 level was significantly increased 1 month after surgery. Comparison of data between the 2 groups found that more patients also had diabetes in the nonelevated group. The postoperative folic acid and VitB12 levels of the elevated group were significantly higher than those of the nonelevated group. More patients had concurrent constipation in the elevated group than in the nonelevated group. Two meaningful variables in LASSO regression analysis were incorporated into the multivariate logistic regression analysis, and constipation was found to be an independent risk factor for the increase in VitB12 after surgery. Of the 199 patients in this study, 111 patients had elevated VitB12 levels after surgery. Among them, 7 patients had peripheral nerve symptoms.Constipation is an independent risk factor for increased VitB12 levels after surgery. High levels of VitB12 may cause some peripheral nerve symptoms. Therefore, it is necessary to pay attention to patients with postoperative constipation, monitor their VitB12 level as soon as possible, and take measures to improve constipation to avoid some adverse reactions caused by elevated VitB12 levels.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34941046 PMCID: PMC8701777 DOI: 10.1097/MD.0000000000028071
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Demographic and clinical data of patients.
| Factors | |
| Age (yr) | 31.29 ± 9.49 |
| Range | 14–74 |
| Gender (n) | |
| Male | 29 |
| Female | 58 |
| Height (cm) | 166.71 ± 8.61 |
| Weight (kg) | 105.90 ± 24.46 |
| BMI (kg/m2) | 37.76 ± 6.18 |
| Mode of surgery (n) | |
| LSG | 49 |
| LSG + JJB | 30 |
| LRYGB | 8 |
| Hematological indexes | |
| Hemoglobin (g/L) | 142.02 ± 14.45 |
| Folic acid (ng/mL) | 7.81 ± 3.61 |
| Vitamin B12 (pg/mL) | 525.42 ± 163.33 |
| ALT (U/L) | 52.19 ± 36.10 |
| AST (U/L) | 32.43 ± 17.47 |
| Creatinine (μmol/L) | 59.96 ± 13.34 |
| Uric acid (μmol/L) | 428.25 ± 124.93 |
| Triglyceride (mmol/L) | 2.04 ± 1.05 |
| Cholesterol (mmol/L) | 4.96 ± 0.85 |
| FBG (mmol/L) | 6.39 ± 3.01 |
| HBA1c (%) | 6.10 ± 1.52 |
| Preoperative complication (n) | |
| T2DM | 19 |
| HBp | 19 |
| Hyperuricemia | 41 |
| Hyperlipidemia | 44 |
| SAS | 56 |
| Fatty liver | 79 |
The results are expressed as mean ± SD or percentages.
ALT = glutamic pyruvic transaminase, AST = glutamic oxaloacetic transaminase, BMI = body mass index, FBG = fasting blood glucose, HBA1c = glycosylated hemoglobin, HBp = high blood pressure, JJB = jejunal bypass, LRYGB = laparoscopic Roux-en-Y gastric bypass, LSG = laparoscopic sleeve gastrectomy, SAS = sleep apnea syndrome, T2DM = type 2 diabetes mellitus.
Retrospective data of serum vitamin B12.
| Follow-up | N (%) | Serum vitamin B12 (pg/mL) | |
| Preoperative | 112 (100) | 468.92 ± 122.22 | <.001 |
| 1 mo | 887.28 ± 390.55 | ||
| Preoperative | 60 (53.57) | 460.91 ± 123.98 | .002 |
| 3 mo | 579.49 ± 307.56 | ||
| Preoperative | 40 (35.71) | 482.79 ± 126.38 | .945 |
| 6 mo | 480.73 ± 178.01 |
The results are expressed as mean ± SD or percentages. The level of significance is P < .05.
Comparison of demographic and clinical data between elevated serum vitamin B12 group and nonelevated serum vitamin B12 group.
| Preoperative Nonelevated group | Elevated group | Postoperative 1 month Nonelevated group | Elevated group | |||
| Gender (n) | .214 | |||||
| Male | 14 | 15 | ||||
| Female | 20 | 38 | ||||
| Age (yr) | 31.12 ± 8.93 | 31.40 ± 9.91 | .895 | |||
| Height (cm) | 167.71 ± 8.94 | 166.08 ± 8.41 | .392 | |||
| Weight (kg) | 108.08 ± 26.19 | 104.51 ± 23.43 | .509 | 95.22 ± 23.85 | 91.91 ± 21.42 | .503 |
| BMI (kg/m2) | 37.99 ± 6.42 | 37.60 ± 6.09 | .775 | 33.47 ± 6.06 | 33.07 ± 5.68 | .752 |
| Mode of surgery (n) | .090 | |||||
| LSG | 17 | 32 | ||||
| LSG + JJB | 11 | 19 | ||||
| LRYGB | 6 | 2 | ||||
| EWL% | 32.81 ± 13.83 | 31.98 ± 9.40 | .739 | |||
| Hematological indexes | ||||||
| Hemoglobin (g/L) | 143.91 ± 15.18 | 140.81 ± 13.97 | .332 | 144.65 ± 11.29 | 141.96 ± 11.28 | .282 |
| Folic acid (ng/mL) | 7.86 ± 3.68 | 7.82 ± 3.59 | .958 | 8.62 ± 4.41 | 11.25 ± 4.86 | .012 |
| Vitamin B12 (pg/mL) | 450.47 ± 82.52 | 477.23 ± 64.29 | .094 | 602.89 ± 99.03 | 1236.52 ± 349.62 | <.001 |
| ALT (U/L) | 54.61 ± 38.52 | 50.51 ± 34.72 | .607 | 46.50 ± 29.50 | 53.17 ± 35.03 | .360 |
| AST (U/L) | 35.63 ± 20.68 | 30.34 ± 14.90 | .169 | 35.10 ± 16.16 | 42.65 ± 23.90 | .110 |
| Creatinine (μmol/L) | 59.04 ± 12.42 | 60.55 ± 13.99 | .611 | 66.31 ± 17.6 | 91.94 ± 54.28 | .558 |
| Uric acid (μmol/L) | 419.98 ± 110.05 | 433.38 ± 134.39 | .628 | 479.59 ± 167.54 | 513.97 ± 202.26 | .411 |
| Triglyceride (mmol/L) | 2.28 ± 1.31 | 1.86 ± 0.83 | .07 | 1.36 ± 0.46 | 1.45 ± 0.56 | .434 |
| Cholesterol (mmol/L) | 5.01 ± 0.97 | 4.90 ± 0.78 | .577 | 4.07 ± 1.05 | 4.12 ± 0.81 | .797 |
| FBG (mmol/L) | 7.10 ± 3.95 | 6.00 ± 2.21 | .101 | 5.30 ± 0.85 | 5.06 ± 0.82 | .204 |
| HBA1c (%) | 6.31 ± 1.71 | 5.95 ± 1.05 | .359 | 5.75 ± 0.78 | 5.34 ± 0.9 | .434 |
| Preoperative complication (n) | ||||||
| T2DM | 12 | 7 | .015 | |||
| HBp | 7 | 12 | .821 | |||
| Hyperuricemia | 18 | 23 | .384 | |||
| Hyperlipidemia | 19 | 25 | .428 | |||
| SAS | 24 | 32 | .332 | |||
| Fatty liver | 33 | 46 | .216 | |||
The results are expressed as mean ± SD or percentages. The level of significance is P < .05.
ALT = glutamic pyruvic transaminase, AST = glutamic oxaloacetic transaminase, BMI = body mass index, EWL = excess weight lost, FBG = fasting blood glucose, HBA1c = glycosylated hemoglobin, HBp = high blood pressure, JJB = jejunal bypass, LRYGB = laparoscopic Roux-en-Y gastric bypass, LSG = laparoscopic sleeve gastrectomy, SAS = sleep apnea syndrome, T2DM = type 2 diabetes mellitus.
The correlation between different postoperative factors and the increase of serum vitamin B12.
| multivitamin tablets | Constipation | Reflux | ||||
| Group | Take | Not take | Yes | No | Yes | No |
| Control group | 24 | 10 | 6 | 28 | 2 | 32 |
| Case group | 42 | 11 | 30 | 23 | 9 | 44 |
| χ2 value | 0.848 | 12.959 | 1.414 | |||
| .357 | <.001 | .234 | ||||
The level of significance is P < .05. Constipation standard: Fewer than 3 defecations per week.[ Reflux standard: There are symptoms of acid regurgitation and heartburn after surgery and must take acid suppressants.
Figure 1Demographic and clinical factor selection using the LASSO binary regression mode. (A) Optimal parameter (lambda) selection in the LASSO model used five-fold cross-validation via minimum criteria.[ The partial likelihood deviance (binomial deviance) curve was plotted versus log (lambda). Dotted vertical lines were drawn at the optimal values by using the minimum criteria and the 1 SE of the minimum criteria (the 1-SE criteria). (B) LASSO coefficient profiles of the 18 factors. A coefficient profile plot was produced against the log (lambda) sequence. Vertical line was drawn at the value selected using five-fold cross-validation, where optimal lambda resulted in 5 features with nonzero coefficients. LASSO = least absolute shrinkage and selection operator, SE = standard error.
Figure 2The results of multivariate logistic regression analysis.
Figure 3The patients with peripheral nerve symptoms after surgery.